

1 **Outpatient clonal propagation propelled rapid regional establishment of an emergent**
2 **carbapenem-resistant *Acinetobacter baumannii* lineage ST499^{Pas}**

3 Juan J. Calix M.D.^{1,2†}, Maria C. Stockler de Almeida M.D.³, Robert F. Potter M.D.⁴, Meghan A.
4 Wallace⁴, Carey-Ann D. Burnham Ph.D.^{1,4,5*}, and Gautam Dantas Ph.D.^{2,4,5,6*}

5 ¹ Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St.
6 Louis, Missouri 63130, United States of America

7 ² The Edison Family Center for Genome Sciences and Systems Biology, Washington University
8 School of Medicine, St. Louis, Missouri 63130, United States of America

9 ³ Department of Medicine, University of Sao Paulo, Sao Paulo, Brazil

10 ⁴ Department of Pathology and Immunology, Washington University School of Medicine, St.
11 Louis, Missouri 63130, United States of America

12 ⁵ Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
13 Missouri 63130, United States of America

14 ⁶ Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri
15 63130, United States of America

16

17 † For correspondence during review: J.J.C. (juancalix@uabmc.edu).

18 Juan J. Calix, MD, PhD

19 University of Alabama in Birmingham Heersink School of Medicine

20 BBRB Room 534, 4523 Clayton Avenue

21 845 19th St S, Birmingham, AL 35205

22 Phone (205) 934-3914 | Fax (205) 996-2416 | Email juancalix@uabmc.edu

23

24 * Corresponding author (after review): G.D. (dantas@wustl.edu)

25

26 **Running title:** CR-*A. baumannii* ST499 rapid emergence

27 **Abstract (199 words)**

28 Combating the evolving health threat posed by carbapenem-resistant *Acinetobacter baumannii*
29 (CRAb) requires knowing how this non-commensal organism establishes regional pools and
30 propagates among at-risk hosts. We report a 2017-2019 surge of CRAb among patients
31 receiving care in a USA multicenter system. This surge occurred during a period of sustained
32 reduction in hospital-acquired CRAb infections and coincided with marked reduction of CRAb
33 cases associated with distinctly more resistant antibiotypes. Isolate whole genome sequencing
34 revealed surge isolates belonged to an emergent Pasteur scheme sequence type 499
35 (ST499^{Pas}). Detailed query of health records guided by isolate genome comparative analyses
36 revealed multiple clonal clusters linked to various outpatient healthcare settings (i.e., long term
37 healthcare facilities, surgical and wound clinics, and other unidentified factors) but no evidence
38 of a shared intrahospital source. We show that emergent CRAb lineages can rapidly establish a
39 regional presence even without gains in breadth of antibiotic resistance and negligible
40 contribution from sustained intrahospital transmission. The emergence of ST499^{Pas} despite
41 regional eradication of other CRAb lineages shows how control efforts could be sidestepped via
42 outpatient epidemiological niches. We also establish an approach to investigate the propagation
43 of CRAb lineages that can inform subsequent local surveillance efforts outside of hospital
44 settings.

45
46 **Key words:** *Acinetobacter baumannii*, molecular epidemiology, healthcare-associated
47 infections, drug resistance

48

49 **Body (3038 words)**

50 **Background**

51 Recognition of carbapenem-resistant *Acinetobacter baumannii* (CRAb) as a top priority
52 in the battle against multidrug resistant infections[1] has prompted efforts to interrupt the
53 propagation of this incidental pathogen among at-risk human hosts. CRAb infections
54 disproportionately impact critically-ill individuals, so surveillance efforts have generally focused
55 on intrahospital microbial reservoirs and outbreaks of hospital-acquired (HA) infections[2, 3].
56 However, reports of CRAb acquisition occurring outside of hospital environments[4-6], raise
57 concerns that outpatient reservoirs could sustain the CRAb epidemic, even if intrahospital
58 transmission is eradicated.

59 Long-term care facilities and acute care hospitals (herein collectively referred as “LTFs”)
60 are implicated as nonhospital “hubs” communicating multidrug resistant organism (MDRO)
61 outbreaks between hospitals[6-11]. Evolutionary adaptations to colonize human gut, skin,
62 genitourinary or upper respiratory niches may facilitate the flow of MDRO pathobionts (e.g.,
63 Enterobacterales, *Staphylococcus*, *Enterococcus* etc.) among these non-hospital environments.
64 Clinically-relevant lineages of environmental MDROs like CRAb, however, are not routinely
65 identified in these commensal niches[3, 12-14] and their propagation is thought to more heavily
66 rely on microbial reservoirs on nosocomial surfaces[3]. Given a presumptive lack of mobility, it
67 remains controversial whether LTFs and other nonhospital reservoirs can spur sustained
68 occurrence of CRAb disease, independent of stable intrahospital pools.

69 *Ab* is a genetically diverse species capable of causing many types of infections[3, 15,
70 16], but only a few global *Ab* lineages like the Pasteur scheme multilocus sequence types 2 and
71 79 (ST2^{Pas} and ST79^{Pas}) have historically accounted for most healthcare-associated CRAb
72 infections[17]. Acquisition of antimicrobial resistance and the ability to colonize nosocomial
73 surfaces likely contribute to these lineages’ fitness in healthcare environments[3]. However, *Ab*

74 demonstrates a high degree of genomic plasticity and access to a deep gene pool[18], which
75 could conceivably foster other lineages incidentally equipped to exploit changing trends in
76 medical practices.

77 Here, we investigated CRAb propagation behaviors via detailed characterization of
78 cases in a large USA healthcare system experiencing a sustained decrease of HA cases (i.e.,
79 cases with index cultures identified >48 hours after hospital admission) but a steady occurrence
80 non-HA (nHA) cases between 2012-2019[16]. The lack of in-hospital outbreaks since 2012
81 affords an opportunity to study CRAb propagation with limited contribution from intrahospital
82 pools, so we employed whole genome sequencing (WGS) of clinical isolates to describe the
83 regional nonhospital arena contributing to CRAb cases. We also tested the hypothesis that
84 CRAb lineages responsible for HA cases pre-2012 are also driving the recent persistence of
85 nHA cases.

86

87 **Methods**

88 **Study location and period.** This study was approved by the Washington University Institutional
89 Review Board (IRB# 201707046 and 201707049) and was performed in five hospitals (herein
90 denoted as BJC1-5) in the affiliated BJC HealthCare System (BJC) from January 1, 2007 to
91 December 31, 2019. BJC is a large integrated inpatient and outpatient healthcare system
92 serving St. Louis, Missouri, USA and surrounding areas. The BJC Epic electronic medical
93 record (EMR) system integrates records from 27 of the 29 hospitals in the area, which allowed
94 for review of an individual's microbiological results, hospitalization notes and outpatient
95 appointments in both BJC and non-BJC systems. Study BJC hospitals and affiliated clinics use
96 a central BJC clinical microbiology laboratory (BJC-CML).

97 **Retrospective case identification and definitions.** The BJC Clinical Data Repository (CDR)
98 was used to identify cases associated with isolates identified as *Acinetobacter* according to

99 automated biochemical methods or matrix-assisted laser desorption/ionization and time of flight
100 mass spectroscopy (MALDI-TOF MS). To account for the unreliability of biochemical methods in
101 distinguishing species within the *Acinetobacter calcoaceticus-baumannii* complex (*Acbc*),
102 isolates reported as “*Acinetobacter baumannii*” or “*Acinetobacter calcoaceticus-baumannii*
103 complex” were binned as “*Acbc* cases”. However, because carbapenem resistance (CR) is
104 rarely reported in non-*baumannii* species and all genotyped carbapenem-resistant isolates in
105 this and a previous U.S. study[19] were confirmed as *Ab*, all CR isolates were labeled CR*Ab*.
106 Case clinical data was obtained from the BJC CDR and by review of EMR, and cases lacking
107 carbapenem susceptibility data (n=98) and hospital outbreak surveillance cultures (n=54) were
108 excluded. Remaining cases were defined by the first culture containing an *Acinetobacter* isolate
109 per patient (“index culture”) and classified into five categories according to tissue source:
110 “respiratory”, “skin and soft tissue/musculoskeletal” (SST/MSK), “urinary”, “blood” (isolates
111 obtained from blood, central lines, or other endovascular devices or grafts), or “other.” Nearly all
112 2017-2019 CR*Ab* cases met “healthcare-associated” criteria[20]. So to better resolve changes
113 in epidemiology, we defined cases as “hospital-acquired” (HA) if index culture was collected ≥ 48
114 hours after hospital admission and prior to discharge, or “nonhospital-acquired” (nHA) for all
115 others, as done before[16].

116 **Clinical isolate banking and definitions.** We performed a prospective, convenience banking
117 of *Acinetobacter* isolates identified in the BJC-CML between July 1, 2017, and May 31, 2019
118 (**Figure S1A**). Isolates identified as an *Acinetobacter* species according to MALDI-TOF MS
119 were eligible for inclusion. If more than one morphologically distinct colony on culture plate was
120 identified as *Acinetobacter*, both colonies were stored. At the end of the banking period, isolates
121 were matched to their respective clinical metadata and processed for genomic analysis. The
122 earliest isolate belonging to a Pasteur scheme multilocus sequence typing (MLST) sequence
123 type (ST) per person was denoted the “index isolate”, with subsequent isolates denoted as
124 “non-index isolates.” Multiple index isolates with unrelated STs could be obtained from a single

125 individual. Herein, banked isolates are named by number (e.g., “isolate 212” denotes
126 WU_MDCI_Ab212, etc.).

127 **Antibiotic susceptibility testing (AST) and antibiotyping.** AST was performed in a CLIA and
128 CAP accredited clinical microbiology laboratory, and interpreted per Clinical and Laboratory
129 Standards Institute guidelines[21]. Per BJC-CML protocols, all *Acinetobacter* isolates are
130 routinely tested by Kirby-Bauer disk diffusion on Mueller-Hinton Agar, for susceptibility to
131 ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), meropenem (MEM), piperacillin-
132 tazobactam (TZP), ampicillin-sulbactam (SAM), trimethoprim-sulfamethaxazole (SXT),
133 gentamicin (GM), and ciprofloxacin (CIP). MEM non-susceptible isolates are reflex tested with
134 tobramycin (TOB), amikacin (AMK), imipenem (IPM), doxycycline (DOX) and minocycline (MIN).
135 Zone of clearance (ZOC) results were obtained from the BJC CDR, and index isolates missing
136 AST results were tested when recovered from frozen cultures. Isolates non-susceptible to either
137 IPM or MEM were defined as “CR”. All cases and isolates were assigned an antibiotype, i.e.,
138 ast-1 thru ast-5, according to their AST results and the algorithm shown in **Figure S1B**. Non-
139 banked cases missing any AST result in the algorithm, were labeled “non-typeable” (nt).

140 **Whole-genome sequencing (WGS) and comparative analysis.** A full description of the well-
141 established processing pipelines[22] used for genomic analyses (**Figure S1**) is provided in the
142 **Supplementary Text**. All sequence files are available under NCBI BioProject PRJNA739144
143 (BioSample accession numbers SAMN19774044-4250) (**Data S2**). Genome sequences of *Ab*
144 isolates from other geographical regions were obtained from NCBI for global comparative
145 analyses (**Data S3**). In a multi-step clonality analysis, “presumptive” clonal clusters were
146 identified using pairwise core genome single nucleotide polymorphisms (cgSNP) and whole
147 genome average nucleotide identity (wgANI). Clustered isolates that shared a common ancestor
148 per subsequent intra-ST phylogenetic analysis were binned into “confirmed” clonal clusters
149 labeled with their respective ST and a number (i.e., “cluster 499-1”). Patients in each cluster

150 were labeled according to when an isolate displaying the pertinent antibiotype was first identified
151 in their clinical timeline (see below), where patient A being the earliest.

152 **Visualizing clinical timelines and suspected transmission sites.** Clinical care received by
153 patients in clusters was detailed by extensive review of EMR. Dates for seven “encounter” types
154 as defined in **Table S1**, were logged. The “wound care/surgical clinic” encounter type was
155 chosen because of the predominance of SST/MSK specimens in a recent BJC study[16]. We
156 defined facilities as “suspected transmission sites” if either (a) a CRAb-positive patient shared
157 an encounter with a different patient within the same cluster with a subsequently positive
158 culture; or (b) a shared encounter preceded positive culture for at least two patients in a cluster.
159 Other shared features incidentally identified in our analysis, are noted in Results.

160 **Statistical analysis.** Univariate analyses were performed with SPSS v25 (IBM, USA) or R
161 software v 3.6.2[23]. Chi-squared or independent t-test was performed for comparing
162 categorical or continuous variables, respectively. Statistical significance was defined as p values
163 <0.05 .

164

165 **Results**

166 **Shifts in CRAb epidemiology in BJC**

167 Of 2,157 *Acba* cases identified in five BJC hospitals in 2007-2019, 2,059 index cultures with
168 carbapenem susceptibility results were eligible for analysis, including 928 (45.1%) CRAb
169 cultures (**Data S1**). The annual percent of CRAb cases being nHA increased from 30-45% in
170 2007-2009 to 60-75% in 2014-2019 (**Figure 1A**). Additionally, latter CRAb isolates were more
171 susceptible to non-carbapenem antibiotics (**Table S2**), with the prevalence of the most narrowly
172 resistant antibiotype, ast-5, increasing from 1.8% of CRAb cases (13/726) prior to 2017 to
173 73.6% (23/40) in 2019 (**Figure 1B**). This coincided with the near disappearance of more

174 broadly resistant antibiotypes that prevailed pre-2012, when CR*Ab* cases were predominantly
175 HA (**Figure 1**).

176

177 **ST499^{Pas} CR*Ab* lineage displaying a distinguishable antibiotype predominates BJC**

178 To better understand this shift in CR*Ab* epidemiology, we performed WGS on 207 isolates
179 representing 53.5% (177/331) and 62.0% (54/87) of total *Acinetobacter* and CR*Ab* cases,
180 respectively, identified in BJC between July 2017 and May 2019. Except for a higher likelihood
181 of being banked in earlier calendar quarters, characteristics of banked and non-banked cases
182 were alike (**Table S3 and S4**). wgANI confirmed 90 index and 20 non-index *Ab* isolates from 87
183 cases (**Data S2**), including cases where strains from distinct Pasteur scheme multilocus
184 sequence types (ST^{Pas}) were co-isolated on the same (isolates 32/33 and 204/205) or
185 subsequent dates (isolates 215/223). All genotyped CR isolates belonged *Ab* STs: ST499^{Pas},
186 ST406^{Pas}, ST2^{Pas}, ST79^{Pas}, ST78^{Pas} and ST1^{Pas} (n= 35 [38.9% of total *Ab* index isolates], 13
187 [14.4%], 5, 3, 2, and 1 respectively) (**Figure 2A**). Isolates within these STs largely shared
188 lineage-associated beta-lactamase gene repertoires, according to antimicrobial resistance gene
189 analysis (**Figure S2A**). Of 35 isolates exhibiting the ast-5 antibiotype, 31 (88.6%) were
190 ST499^{Pas}. The other four (i.e., isolates 39, 165, 233, and 249) were outlier ST406^{Pas} isolates
191 lacking *ant(2'')-Ia/aadA2* and *sul1*, the genes putatively conferring aminoglycoside and
192 sulfonamide resistance, respectively, in all other ST406^{Pas} genomes and the outlying ST499^{Pas}
193 isolate 212 (**Figure 2** and **Data S4**).

194 Comparison of the AST ZOC data of 2017-2019 *Ab* cases (**Figure 2B-2D**, **Figure S2B**,
195 **Table S5**) revealed that genotyped ST499^{Pas} and non-genotyped ast-5 isolates composed a
196 distinctively homogenous group. As a group they displayed (a) intermediate SXT susceptibility
197 lower than most *CsAb* isolates and ST406^{Pas} outliers that lacked *sul1* (resulting in the variation
198 reported in their SXT AST results, **Figure 2A and 2B**); (b) ZOC to tetracyclines and
199 aminoglycosides comparable to other susceptible CR*Ab*; and (c) characteristic ZOC distribution

200 to each β -lactam antibiotic, including high resistance to MEM/IPM (**Figure 2C**) but intermediate
201 susceptibility to CAZ/FEP (**Figure S2B**). Altogether, this supported that ST499^{Pas} is responsible
202 for the recent surge of ast-5 isolates observed in BJC (**Figure 1B**).

203

204 **ST499^{Pas} clonal clusters were linked to regional nonhospital settings**

205 A global phylogenetic analysis incorporating 510 genomes of *Ab* isolates from other regions
206 revealed that BJC ST2^{Pas} and ST406^{Pas} isolates represented multiple subgroups within their
207 respective global clades (**Figure S3**), consistent with sporadic introductions of these ST into our
208 cohort. In contrast, a single phylogenetic cluster contained all BJC ST499^{Pas} isolates except for
209 the outlying isolate 212, which was obtained from an individual transferred from an unaffiliated
210 hospital in the Southeastern USA. ST499^{Pas} isolates were regularly isolated throughout 2017-
211 2019 from various tissues sources and in four of the five study hospitals, and only 13 of 35
212 cases met HA criteria (**Figure 2**). So, despite sharing a recent common ancestor, ST499^{Pas}
213 cases unlikely resulted from a spatiotemporally hyperlocalized outbreak.

214 To understand how BJC ST499^{Pas} emerged in our region, we assigned presumptive
215 clonal relationships between isolates according to cutoffs of cgSNP distance ≤ 5 and wgANI
216 $\geq 99.997\%$ (**Figure 3A-B**). The use of more inclusive cutoffs (i.e., cgSNP distance 10-30 and
217 wgANI 99.990-99.995%) yielded minimal changes to presumptive clusters in sensitivity
218 analyses (**Figure S4**). Cluster composition was subsequently confirmed if isolates shared a
219 common ancestor according to ST^{Pas}-specific core genome phylogeny (**Figure 3C-D**). All non-
220 index and corresponding index isolates clustered closely (**Figure 3**), and comparable results
221 were obtained when clustering by either ST^{Pas}-specific accessory gene content or adjusting for
222 potential recombination events (**Figure S5**).

223 We detected six ST499^{Pas} (**Figure 3C and 4**) and one ST406^{Pas} clonal clusters (**Figure**
224 **3D**), and suspected transmission sites were identified in four ST499^{Pas} clusters (**Figure 4C-F**).
225 Cluster 499-1 was composed of four patients (A-D) with recent exposure to clinic 4 (CLIN4)

226 and/or CLIN5; two overlapping residents of long-term care facility 6 (LTF6) patients colonized
227 with the phylogenetically distinct isolates 210 and 217 (**Figure 4B**, patients D and E); and two
228 patients with multiple incidences of ST499^{Pas}/ast-5 isolates across many months (G, H), who
229 had resided in LTF9 (**Figure 4C**). Patient 499-1F lacked an obvious link, except for recurrent
230 admission to BJC1. Three of four cluster 499-2 patients repeatedly visited CLIN2 (**Figure 4D**),
231 and all cluster 499-5 patients had resided in LTF10 during a 3-month span (**Figure 4E**). Lastly,
232 499-6 was the only cluster containing individuals (A-D) enrolled in the local Veterans Affairs
233 (VA) medical system. Though VA records were not available, patients B-D were long-term
234 residents of LTF26 (**Figure 4F**). Shared exposures were not identified for clusters 499-3, cluster
235 499-4 and 406, but no single hospital linked these cases, either. Moreover, patients 499-3B,
236 499-3D and 499-4D were not hospitalized in a study hospital prior to their index culture (**Figure**
237 **5**). In summary, various contemporary clonal networks were linked to cluster-specific,
238 nonhospital settings that likely facilitated their propagation.

239

240 **Discussion**

241 We report sharp rise of ST499^{Pas} CRAb cases in the St. Louis region, which remarkably
242 coincided with the decline of CRAb displaying differing antibiotypes. ST2^{Pas} and ST79^{Pas}, two of
243 the top three globally prevalent CRAb lineages[17], overwhelmingly predominated Ab cases in
244 recent molecular surveys at two other USA Midwest academic hospital systems (**Figure S3**)[24,
245 25], and evidence supports these lineages previously predominated in our region. The ast-1/-2
246 or ast-4 antibiotypes characteristic of BJC ST2^{Pas} or ST79^{Pas} isolates, respectfully (**Figure 2A**),
247 were displayed by >85% of pre-2016 BJC CRAb isolates but only 17% of CRAb in 2019.
248 Furthermore, in a U.S. nationwide CRAb survey conducted in 2008-2009, all isolates
249 contributed by BJC were ST2^{Pas} or ST79^{Pas} (n=11 and 2, respectively)[19]. While these putative
250 pre-2012 BJC ST2^{Pas} infections were overwhelmingly HA and arguably resulted from clonal,
251 intrahospital outbreaks, recent ST2^{Pas} cases were seemingly result of sporadic, unrelated clones

252 **(Figure S3)**. Altogether, these findings imply the elimination of conditions that were once
253 conducive to the propagation of major global lineages in the region.

254 Conversely, the coinciding emergence of BJC ST499^{Pas} reflects the lineage's capacity to
255 exploit a different epidemiological space. In contrast to CR*Ab* propagation centering on inpatient
256 and critical care settings pre-2012, we appreciated no contribution from intrahospital
257 transmission to the ongoing occurrence of ST499^{Pas} **(Figure 6)**. Consistent with local CR*Ab*
258 cases transitioning towards nHA SST/MSK and urinary cases[16], ST499^{Pas} propagation
259 appeared to center around clinics serving patients with chronic wounds and LTFs **(Figure 4)**.
260 Though the latter are recognized hotspots for CR*Ab* transmission[6-8], wound clinics have been
261 historically underappreciated. We observed multiple instances (e.g., patients 499-1B, 499-1G,
262 499-1H, 499-4D, etc.) in which ST499^{Pas} was isolated over the span of up to 12 months from a
263 single patient, establishing that individuals residing in the community are either persistently
264 colonized or repeatedly exposed to long-lived CR*Ab* pools outside of hospitals. This merits
265 further investigation, as these asymptomatic individuals could serve as incidental vectors
266 communicating outbreaks between different locations and exposing individuals at risk for severe
267 disease[26].

268 Pasteur scheme ST499^{Pas} (not to be confused with the unrelated Oxford scheme
269 ST499^{Oxf} [27]) was first described in the US in a 2010 blood isolate [28], although the single
270 locus variant ST123^{Pas} was detected once among Las Vegas 2008-2009 isolates [19].
271 Remarkably, though the 2008-2009 U.S. nationwide survey identified no ST499 isolates [19], a
272 subsequent analysis of CR*Ab* in four U.S. hospital centers (performed concurrently and
273 independently from our study) revealed ST499^{Pas} as the second most prevalent lineage, second
274 only to ST2^{Pas} [29]. ST499^{Pas} is not part of any major global clone and, apart from a three 2014
275 isolates in Tanzania and a one 2000 isolate in Australia, has been exclusively identified in North
276 America[17, 30, 31]. Though capable of acquiring genes encoding broader resistance, as
277 evidenced by isolate 212 **(Figure 2)**, ST499^{Pas} displayed the most narrow CR*Ab* antibiotic type,

278 effectively dismissing antibiotics as the main driver of its emergence. Importantly, the fact that
279 no ST499^{Pas} intrahospital outbreak has been reported to our knowledge, does not preclude its
280 capacity to establish sustained intrahospital transmission and disease (akin to preceding
281 lineages), if given the opportunity.

282 Though our study is limited to describing CR*Ab* in a single metropolitan area, BJC is
283 representative of modern healthcare systems[24] where increasing reliance on outpatient
284 services for managing chronic illnesses may facilitate outpatient CR*Ab* propagation.
285 Surveillance studies remain the gold standard for tracking MDRO transmission trends, but non-
286 targeted surveillance of outpatient environments can be resource intensive and complicated by
287 local practice variations. Furthermore, the utility of surveillance screening of *Ab* has been
288 brought into question[32], in part due to an incomplete understanding of *Ab* carriage and natural
289 reservoirs. As shown here, combining genomic analysis of clinical isolates with a regionally
290 integrated EMR system represents an alternative that can be especially valuable for guiding
291 larger subsequent surveillance efforts.

292 Importantly, the resolution afforded by employing WGS and multilevel criteria for clonal
293 clusters was key to disentangling CR*Ab* networks in a patient population with overlapping
294 exposures. For example, patient 499-1H admission to LTF10 (**Figure 4A**) coincided with the
295 LTF10 admission of cluster 499-5 patients (**Figure 4E**), but unambiguous assignment of isolate
296 237 to cluster 499-1, instead, implicates LTF9. Though our convenience cohort was
297 representative of the overall BJC isolate population, being unable to assign shared exposures to
298 some ST499^{Pas} clusters may have resulted from failure to capture keystone cases, including
299 possible cases of intrahospital transmission. Also, future investigations should include other
300 healthcare exposures associated with chronic medical conditions, including home health
301 services, emergency room visits, non-wound/surgical clinics, and other outpatient services (e.g.,
302 radiology, dialysis, infusion centers, etc.). Lastly, the phylogenetic diversity of BJC Cs*Ab*
303 isolates (**Figure 2A**) implies exposure to a deep *Ab* gene pool existing outside of healthcare

304 settings and highlights that *Ab* is an environmental species that survives in various human-
305 independent niches that remain to be identified[2]. The outpatient arena represents the next
306 front in the fight against *CRAb* disease, and elucidating how *CRAb* persists in nonhospital
307 settings will be a cornerstone for future combat strategies.

308

309

310 **Footnotes**

311 **Competing interests.** The authors declare no competing interests in regards to this work.

312 **Funding.** This work was supported in part by awards to G.D. through the National Institute of
313 Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child
314 Health & Human Development of the National Institutes of Health (NIH) under award numbers
315 U01 AI123394 and R01 HD092414, and awards to J.J.C by the NIH under award number K08
316 AI148582. The content is solely the responsibility of the authors and does not necessarily
317 represent the official views of the funding agencies.

318 **Prior presentations.** This research was presented in part as an oral abstract (#154) at ID Week
319 in October, 2020 and as an oral abstract at the AcinetoVibes Online Conference in June, 2022.

320 **For reprints** please contact Gautam Dantas, 4515 McKinley Ave, Rm 5314, Box 8510, St
321 Louis, MO 63110. [p] (314) 362-7238 [f] (314) 362-2156 [e] dantas@wustl.edu.

322 **Authors' change in affiliation.** JJC currently is an Assistant Professor in the Division of
323 Infectious Diseases, Department of Medicine, University of Alabama at Birmingham Heersink
324 School of Medicine, Birmingham, Alabama, USA. Correspondence for JJC should be
325 addressed to Bevill Biomedical Research Building, Room 534, 845 19th St S, Birmingham, AL
326 35205.

327 **Authors' contributions.** JJC conceived and designed the study. MCSA performed health
328 record review. RFP was involved with design of comparative genomic analysis. CAB and MAW
329 collected samples. JJC performed specimen handling, genome sequencing, data management
330 and statistical analysis. JJC prepared figures and tables, and wrote the first draft of the
331 manuscript. CAB and GD analyzed and discussed data and critically revised the manuscript.

332 **Acknowledgements.** The authors thank the Edison Family Center for Genome Sciences &
333 Systems Biology at WUSM staff, Eric Martin, Brian Koebbe, Jessica Hoisington-López, and
334 MariaLynn Crosby for technical support in high-throughput sequencing and computing. The

335 authors thank the members of the Dantas and Burnham lab for helpful comments and critiques.

336 The authors thank Dorothy Sinclair and Cherie Hill for their essential and expert contributions in
337 medical record data retrieval for this study.

338 **Ethics approval and consent to participate.** This study was approved by the Institutional
339 Review Board of Washington University in St. Louis (IRB# 201707046 and 201707049). A
340 waiver of informed consent was granted as all specimens and clinical records were obtained
341 during routine clinical care and many patients were already deceased or would otherwise have
342 been unable to be contacted.

343 **Availability of data and materials.** Sequence read files and constructed genomes for
344 sequenced BJC isolates are available on NCBI under BioProject PRJNA739144, and
345 BioSample accession numbers SAMN19774044-4250. The datasets used and analyzed during
346 the current study are available from JJC on reasonable request. Access to retrospective clinical
347 case datasets including patient demographics and specific dates is restricted due to patient
348 privacy protections.

349

350

351

352

References

1. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* **2018**; 18:318-27.
2. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* **2008**; 21:538-82.
3. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of *Acinetobacter* Infections: a Century of Challenges. *Clin Microbiol Rev* **2017**; 30:409-47.
4. Hoffman-Roberts H, Scoble P, Tabak YP, Mohr J, Johannes RS, Gupta V. National Prevalence of Multidrug-Resistant *Acinetobacter baumannii* Infections in the Ambulatory and Acute Care Settings, Including Carbapenem-Resistant *Acinetobacter* Infections, in the United States in 2015. *Open Forum Infectious Diseases* **2016**; 3:1488-.
5. Villar M, Cano ME, Gato E, et al. Epidemiologic and clinical impact of *Acinetobacter baumannii* colonization and infection: a reappraisal. *Medicine (Baltimore)* **2014**; 93:202-10.
6. Sengstock DM, Thyagarajan R, Apalara J, Mira A, Chopra T, Kaye KS. Multidrug-resistant *Acinetobacter baumannii*: an emerging pathogen among older adults in community hospitals and nursing homes. *Clin Infect Dis* **2010**; 50:1611-6.
7. Mortensen E, Trivedi KK, Rosenberg J, et al. Multidrug-resistant *Acinetobacter baumannii* infection, colonization, and transmission related to a long-term care facility providing subacute care. *Infect Control Hosp Epidemiol* **2014**; 35:406-11.
8. Furuno JP, Hebden JN, Standiford HC, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* and *Acinetobacter baumannii* in a long-term acute care facility. *Am J Infect Control* **2008**; 36:468-71.

9. Buser GL, Cassidy PM, Cunningham MC, et al. Failure to Communicate: Transmission of Extensively Drug-Resistant bla OXA-237-Containing *Acinetobacter baumannii*-Multiple Facilities in Oregon, 2012-2014. *Infect Control Hosp Epidemiol* **2017**; 38:1335-41.
10. Townsend J, Park AN, Gander R, et al. *Acinetobacter* infections and outcomes at an academic medical center: a disease of long-term care. *Open Forum Infect Dis* **2015**; 2:ofv023.
11. Rodriguez-Villodres A, Martin-Gandul C, Penalva G, et al. Prevalence and Risk Factors for Multidrug-Resistant Organisms Colonization in Long-Term Care Facilities Around the World: A Review. *Antibiotics (Basel)* **2021**; 10.
12. Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. Reservoirs of Non-*baumannii* *Acinetobacter* Species. *Front Microbiol* **2016**; 7:49.
13. Griffith ME, Ceremuga JM, Ellis MW, Guymon CH, Hospenthal DR, Murray CK. *Acinetobacter* skin colonization of US Army Soldiers. *Infect Control Hosp Epidemiol* **2006**; 27:659-61.
14. Ducarmon QR, Terveer EM, Nooij S, et al. Microbiota-associated risk factors for asymptomatic gut colonisation with multi-drug-resistant organisms in a Dutch nursing home. *Genome Med* **2021**; 13:54.
15. Di Venanzio G, Flores-Mireles AL, Calix JJ, et al. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic *Acinetobacter baumannii* chromosomal genes. *Nat Commun* **2019**; 10:2763.
16. Calix JJ, Burnham JP, Feldman MF. Comparison of the Clinical Characteristics of Hospital-Acquired and Non-Hospital-Acquired *Acinetobacter calcoaceticus-baumannii* Complex in a Large Midwest US Health Care System. *Open Forum Infect Dis* **2019**; 6:ofz423.
17. Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microb Genom* **2019**; 5.

18. Chan AP, Sutton G, DePew J, et al. A novel method of consensus pan-chromosome assembly and large-scale comparative analysis reveal the highly flexible pan-genome of *Acinetobacter baumannii*. *Genome Biol* **2015**; 16:143.
19. Adams-Haduch JM, Onuoha EO, Bogdanovich T, et al. Molecular epidemiology of carbapenem-nonsusceptible *Acinetobacter baumannii* in the United States. *J Clin Microbiol* **2011**; 49:3849-54.
20. Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med* **2002**; 137:791-7.
21. Institute. CaLS. Performance standards for antimicrobial susceptibility testing; 27th edition. CLSI document M100-S27. Wayne, PA: Clinical and Laboratory Standards Institute. . **2017**.
22. Potter RF, Lainhart W, Twentyman J, et al. Population Structure, Antibiotic Resistance, and Uropathogenicity of *Klebsiella variicola*. *mBio* **2018**; 9.
23. Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria **2020**.
24. Adams MD, Wright MS, Karichu JK, et al. Rapid Replacement of *Acinetobacter baumannii* Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. *mBio* **2019**; 10.
25. Fitzpatrick MA, Ozer EA, Hauser AR. Utility of Whole-Genome Sequencing in Characterizing *Acinetobacter* Epidemiology and Analyzing Hospital Outbreaks. *J Clin Microbiol* **2016**; 54:593-612.
26. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for *Acinetobacter baumannii* nosocomial bacteremia in critically ill patients: a cohort study. *Clin Infect Dis* **2001**; 33:939-46.

27. Zowawi HM, Sartor AL, Sidjabat HE, et al. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates in the Gulf Cooperation Council States: dominance of OXA-23-type producers. *J Clin Microbiol* **2015**; 53:896-903.
28. Ozer EA, Fitzpatrick MA, Hauser AR. Draft Genome Sequence of *Acinetobacter baumannii* Strain ABBL099, a Multidrug-Resistant Clinical Outbreak Isolate with a Novel Multilocus Sequence Type. *Genome announcements* **2014**; 2.
29. Iovleva A, Mustapha MM, Griffith MP, et al. Carbapenem-Resistant *Acinetobacter baumannii* in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. *mBio* **2022**; 13:e0275921.
30. Kumburu HH, Sonda T, van Zwetselaar M, et al. Using WGS to identify antibiotic resistance genes and predict antimicrobial resistance phenotypes in MDR *Acinetobacter baumannii* in Tanzania. *J Antimicrob Chemother* **2019**; 74:1484-93.
31. Meumann EM, Anstey NM, Currie BJ, et al. Whole-Genome Sequencing to Differentiate Relapse From Reinfection in Community-Onset Bacteremic *Acinetobacter baumannii* Pneumonia. *Open Forum Infect Dis* **2019**; 6:ofz263.
32. Marchaim D, Navon-Venezia S, Schwartz D, et al. Surveillance cultures and duration of carriage of multidrug-resistant *Acinetobacter baumannii*. *J Clin Microbiol* **2007**; 45:1551-5.

Supplementary Tables

Table S1. List of clinical and epidemiological "elements" identified in electronic health record review. ^a, shapes and abbreviations used in clinical timelines in Figures 4 and S9.

	Element type	Timeline key ^b	Definition	Collected information
1	Postive cultures		Cultures containing <i>Ab</i> or <i>Acbc</i> isolates of interest	Culture collection date
	ST406/ST409 isolate	### [red triangle]	Cultures containing isolate obtained for WGS and typed by MLST	Anatomical and/or tissue source of culture
	ast-3/ast-5 isolate	* [orange triangle]	Cultures containing isolate NOT obtained for WGS but identified by EHR	Anatomical and/or tissue source of culture
2	Negative cultures		Cultures from same anatomical and/or tissue source as "positive cultures", but NOT containing <i>Ab</i> or <i>Acbc</i> isolates of interest	Culture collection date
	Other <i>Ab</i> isolate	O [black triangle]	Cultures containing <i>Ab</i> or <i>Acbc</i> isolates, but NOT of interests, according to MLST or EHR	Anatomical and/or tissue source of culture
	No <i>Ab</i> isolate	[gray triangle]	Cultures containing non- <i>Acinetobacter</i> isolates or which grew no organisms	Anatomical and/or tissue source of culture
3	Hospitalizations	[colored box]	Admission to hospital for >24 hours	Admission, hospital-to-hospital transfer (if pertinent) and discharge dates
	BJC	BJC1-7	Admission to one of fifteen BJC hospitals in our region	Emergency room (ER) records and discharge summary, for origination and disposition information
	Other hospital	OH1-7	Admission to other hospitals, as noted in EHR	ER records and discharge summary, for origination and disposition information
	Unknown hospital	"unknown"	Admission to/transfer from hospital, whose identity was not clearly stated in EHR	
* NOTE: Emergency room and urgent care clinic encounters WITHOUT admission, were not included in final analysis				
4	Long-term care facility encounters	LTF1-29 [colored bar]	Admission to and/or residency in long-term care, long-term acute care, skilled nursing home, or assisted living facilities	Admission and discharge dates
*NOTE: Unless clearly delineated in EHR, duration of LTF encounter was presumed according to preceding discharge records, subsequent admission records (i.e., whether patient was admitted from LTF or home), and outpatient records.				
5	Infectious disease clinic encounters	CLIN1 [blue circle]	In-person appointments at main BJC outpatient infectious disease clinic	Appointment date (excluded telemedicine and "no-show" appointments)
6	Wound care/surgical clinic encounters	CLIN2-13 [colored circle]	In-person appointments to any wound care specialty or general surgical outpatient clinic, as noted in EHR	Appointment date (excluded telemedicine and "no-show" appointments)
7	Expiration/comfort care	X	Person expired or decision to transition to comfort care	Date of expiration note, or date of progress note/discharge summary detailing transition to comfort care measures
8	Suspected transmission sites	[shaded areas between patients]	either (1) an encounter for a patient colonized with a CR <i>Ab</i> isolate preceded the encounter of another patient who subsequently had a positive culture; or (2) encounters preceded positive culture for at least two patients in a cl.	

Table S2. Antibiotic resistance rates among CRAB isolates, BJC 2007-2019. p-values are comparing non-susceptibility rates of isolates obtained from 2007-12 versus 2013-19, by Fisher's Exact Test. s, susceptible; ns, non-susceptible; NA, susceptibility data not available; %ns, percent non-susceptible

	Ciprofloxacin				Gentamicin				Trimethoprim/Sulfamethaxazole				Tetracycline and/or Doxycycline				Ampicillin/Sulbactam			
	s	ns	NA	%ns	s	ns	NA	%ns	s	ns	NA	%ns	s	ns	NA	%ns	s	ns	NA	%ns
2007	0	60	11	100.0	19	52	0	73.2	4	66	1	94.3	2	26	43	92.9	7	21	43	75.0
2008	0	102	25	100.0	54	73	0	57.5	5	122	0	96.1	27	99	1	78.6	25	101	1	80.2
2009	1	120	21	99.2	82	60	0	42.3	6	136	0	95.8	67	68	7	50.4	26	109	7	80.7
2010	0	85	24	100.0	70	39	0	35.8	3	106	0	97.2	55	53	1	49.1	73	28	8	27.7
2011	0	111	1	100.0	53	58	1	52.3	3	108	0	97.3	61	51	0	45.5	51	22	39	30.1
2012	0	44	0	100.0	10	34	0	77.3	4	40	0	90.9	20	24	0	54.5	29	14	1	32.6
2013	0	53	0	100.0	22	31	0	58.5	12	40	1	76.9	23	29	1	55.8	13	40	0	75.5
2014	2	43	0	95.6	27	18	0	40.0	6	39	0	86.7	22	23	0	51.1	17	28	0	62.2
2015	1	57	0	98.3	37	19	2	33.9	10	48	0	82.8	19	38	1	66.7	30	24	4	44.4
2016	0	44	0	100.0	22	22	0	50.0	9	34	1	79.1	14	8	22	36.4	23	15	6	39.5
2017	0	30	0	100.0	17	13	0	43.3	4	26	0	86.7	27	3	0	10.0	19	11	0	36.7
2018	0	40	0	100.0	27	13	0	32.5	13	27	0	67.5	36	4	0	10.0	29	11	0	27.5
2019	2	51	0	96.2	47	6	0	11.3	27	26	0	49.1	49	4	0	7.5	37	16	0	30.2
TOTAL 2007-12	1	522	82	99.8	288	316	1	52.3	25	578	1	95.9	232	321	52	58.0	211	295	99	58.3
TOTAL 2013-19	5	318	0	98.5	199	122	2	38.0	81	240	2	74.8	190	109	24	36.5	168	145	10	46.3
p =	0.0327				<0.0001				<0.0001				<0.0001				0.0009			

Table S3. Clinical characteristics *Acinetobacter* cases with banked and non-banked

isolates, BJC 7/2017-5/2019. ^a, p-value comparing genotyped to not genotyped cases, according to Fisher's exact test. The proportion of isolates belonging to >2 categories, was compared for "tissue source", "isolation date" and "hospital". ^b, Cases lacking AST results in the EMR were excluded from analysis.

n=	Total 331	Banked 177	Non-banked 154	p
Patient demographic				
Adult, n (%)	272 (82.2)	144 (81.4)	128 (72.3)	0.7736
Female, n (%)	135 (40.8)	70 (39.5)	65 (36.7)	0.6546
Case types				
Acbc/Aspp	174/157	98/79	76/78	0.3207
Tissue source				0.4579
Blood	45 (13.6)	20 (11.3)	25 (16.2)	
Intrabdominal	3 (0.9)	2 (1.1)	1 (0.6)	
Other	11 (3.3)	4 (2.3)	7 (4.5)	
Respiratory	89 (26.9)	53 (29.9)	36 (23.4)	
SST/MSK	145 (43.8)	76 (42.9)	69 (44.8)	
Urinary	38 (11.5)	22 (12.4)	16 (10.4)	
Sole isolate	171 (51.7)	99 (55.9)	72 (46.8)	0.0996
HA cases, n (%)	73 (22.1)	40 (22.6)	33 (21.4)	0.8944
Epidemiology				
Isolation date				<0.0001
2017-Q3	53 (16.0)	38 (21.5)	15 (9.7)	
2017-Q4	36 (10.9)	34 (19.2)	2 (1.3)	
2018-Q1	45 (13.6)	17 (9.6)	28 (18.2)	
2018-Q2	33 (10.0)	19 (10.7)	14 (9.1)	
2018-Q3	58 (17.5)	19 (10.7)	39 (25.3)	
2018-Q4	40 (12.1)	22 (12.4)	18 (11.7)	
2019-Q1	41 (12.4)	22 (12.4)	19 (12.3)	
2019-Q2	25 (7.6)	6 (3.4)	19 (12.3)	
Hospital				0.2418
BJC1	158 (47.7)	87 (49.2)	71 (40.1)	
BJC2	67 (20.2)	30 (16.9)	37 (20.9)	
BJC3	28 (8.5)	12 (6.8)	16 (9.0)	
BJC4	24 (7.3)	15 (8.5)	9 (5.0)	
BJC5	54 (16.3)	33 (18.6)	21 (11.9)	
AST				
CRO	323/63 (83.7)	146/29 (83.4)	177/34 (83.9)	1
CAZ	101/226 (30.9)	61/114 (34.9)	40/112 (26.1)	0.5526
FEP	83/244 (25.4)	53/122 (30.3)	30/122 (19.7)	0.0308
MEM	87/240 (26.6)	54/121 (30.9)	33/119 (21.7)	0.078
TZP	107/218 (32.9)	60/115 (34.3)	47/103 (31.3)	0.6361
CIP	102/224 (31.3)	59/116 (33.7)	43/108 (28.5)	0.3389
SAM	27/280 (8.8)	17/151 (10.1)	10/129 (7.2)	0.4221
GM	31/296 (9.5)	18/157 (10.3)	13/139 (8.6)	0.7059
SXT	79/246 (24.3)	47/128 (26.9)	32/118 (21.3)	0.2995

Table S4. Clinical characteristics CRAb cases with banked and non-banked isolates, BJC

7/2017-5/2019. ^a, p-value comparing genotyped to not genotyped cases, according to Fisher's exact test. The proportion of isolates belonging to >2 categories, was compared for "tissue source", "isolation date" and "hospital". ^b, One genotyped isolate was missing TOB susceptibility data in the EMR. ^c, isolate initially reported as Aspp was actually *A. baumannii* by sequencing analysis.

n=	Total	Banked	Non-banked	p
	87	54	33	
Patient demographic				
Adult, n (%)	87 (100)	54 (100)	33 (100)	1
Female, n (%)	29 (33.3)	16 (29.6)	13 (39.4)	0.3602
Case types				
Acbc/Aspp	86/1 ^c	53/1 ^c	33/0	
Tissue source				0.4241
Blood, n (%)	4 (4.6)	2 (3.7)	2 (6.1)	
Respiratory, n (%)	13 (14.9)	8 (14.8)	5 (15.2)	
SST/MSK, n (%)	58 (66.7)	34 (63.0)	24 (72.7)	
Urinary, n (%)	12 (13.8)	10 (18.5)	2 (6.1)	
Sole isolate, n (%)	43 (49.4)	29 (53.7)	14 (43.4)	0.3786
HA cases, n (%)	24 (27.6)	13 (24.1)	11 (33.3)	0.459
Epidemiology				
Isolation date				0.0001
2017-Q3	10 (11.5)	10 (18.5)	0	
2017-Q4	10 (11.5)	10 (18.5)	0	
2018-Q1	10 (11.5)	3 (5.6)	7 (21.2)	
2018-Q2	7 (8.1)	6 (11.1)	1 (3.0)	
2018-Q3	12 (13.8)	6 (11.1)	6 (18.2)	
2018-Q4	14 (16.1)	8 (14.8)	6 (18.2)	
2019-Q1	17 (19.5)	10 (18.5)	7 (21.2)	
2019-Q2	7 (8.1)	1 (1.9)	6 (18.2)	
Hospital				0.7899
BJC1	45 (51.7)	29 (53.7)	16 (48.5)	
BJC2	29 (33.3)	16 (29.6)	13 (39.4)	
BJC3	10 (11.5)	6 (11.1)	4 (12.1)	
BJC4	2 (2.3)	2 (3.7)	0	
BJC5	1 (1.2)	1 (1.9)	0	
AST				
CRO	87/0 (100)	54/0 (100)	33/0 (100)	1
CAZ	73/14 (83.9)	45/9 (83.3)	28/5 (84.8)	1
FEP	73/14 (83.9)	47/7 (87.0)	26/7 (78.8)	0.3725
IPM	85/2 (97.7)	53/1 (98.1)	32/1 (97.0)	1
TZP	85/2 (97.7)	53/1 (98.1)	32/1 (97.0)	1
SAM	27/60 (31.0)	17/37 (31.5)	10/23 (30.3)	1
GM	24/63 (27.6)	14/40 (25.9)	10/23 (30.3)	0.8052
TOB ^b	19/67 (22.1)	11/42 (20.1)	8/25 (24.2)	1
AMK	6/81 (6.9)	5/49 (9.3)	1/32 (3.0)	0.4013
SXT	53/34 (60.9)	34/20 (63.0)	19/14 (57.6)	0.6556
DOX	8/79 (10.1)	4/50 (7.4)	4/29 (12.1)	0.4713
MIN	4/83 (4.6)	3/51 (5.6)	1/32 (3.0)	1
CIP	87/0 (100)	54/0 (100)	33/0 (100)	1

Table S5. Summary of AST data for each group of *A. baumannii* isolates from Figures 2b-d and S2b. ^a, number of isolates with valid or missing susceptibility testing data for each antibiotic; ^b, All median, minimum, maximum and percentile values are zone of clearance sizes, mm

			Ceftazidime	Cefepime	Meropenem	Imipenem	Piperacillin/ Tazobactam	Ampicillin/ Sulbactam	Gentamicin	Amikacin	Tobramycin	Doxycycline	Minocycline	Trimethoprim/ Sulfamethoxazole	Ciprofloxacin	
CsAb	N ^a	Valid	133	133	133	6	133	101	133	6	6	6	6	133	133	
		Missing	0	0	0	127	0	32	0	127	127	127	127	127	0	0
	Median ^b		20.00	23.00	25.00	29.00	23.00	27.00	23.00	22.00	21.00	24.50	26.00	23.00	26.00	
	Minimum		6.00	6.00	18.00	24.00	6.00	16.00	6.00	20.00	6.00	17.00	24.00	6.00	6.00	
	Maximum		28.00	34.00	42.00	32.00	36.00	33.00	33.00	26.00	24.00	25.00	27.00	33.00	37.00	
	Percentiles	25		19.00	21.00	24.00	26.25	21.00	25.00	22.00	20.75	6.00	20.75	25.50	20.00	24.00
		75		22.00	25.00	27.00	31.25	25.00	28.00	24.00	23.75	22.50	25.00	26.25	24.00	28.00
ST499/ast-5	N	Valid	71	71	71	71	71	71	71	71	70	71	70	71	71	
		Missing	0	0	0	0	0	0	0	0	0	1	0	1	0	0
	Median		16.00	13.00	6.00	6.00	10.00	18.00	22.00	23.00	22.50	15.00	19.00	16.00	6.00	
	Minimum		6.00	6.00	6.00	6.00	6.00	6.00	11.00	16.00	17.00	13.00	16.00	6.00	6.00	
	Maximum		23.00	24.00	8.00	13.00	17.00	24.00	26.00	25.00	25.00	25.00	26.00	23.00	23.00	
	Percentiles	25		15.00	11.00	6.00	6.00	6.00	13.00	18.00	22.00	21.00	15.00	18.00	14.00	6.00
		75		17.00	17.00	6.00	7.00	11.00	19.00	23.00	24.00	24.00	16.00	20.00	18.00	6.00
ST406/ast-3	N	Valid	30	30	30	30	30	30	30	30	29	30	29	30	30	
		Missing	0	0	0	0	0	0	0	0	0	1	0	1	0	0
	Median		6.00	6.00	8.50	12.00	15.50	24.50	6.00	23.00	10.00	16.00	20.00	6.00	6.00	
	Minimum		6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	13.00	17.00	6.00	6.00	
	Maximum		15.00	12.00	17.00	26.00	22.00	27.00	25.00	27.00	25.00	24.00	26.00	27.00	17.00	
	Percentiles	25		6.00	6.00	6.00	10.75	15.00	22.00	6.00	19.75	6.00	15.00	19.00	6.00	6.00
		75		6.00	6.00	10.00	13.00	16.25	26.00	11.00	25.25	12.50	18.25	22.00	6.75	6.00
Other CRAb	N	Valid	24	24	24	24	24	24	24	24	24	24	24	24	24	
		Missing	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Median		8.50	11.00	6.00	7.50	9.00	12.50	20.00	21.50	19.50	13.50	17.50	6.00	6.00	
	Minimum		6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	12.00	6.00	6.00	
	Maximum		23.00	24.00	25.00	18.00	24.00	28.00	30.00	27.00	26.00	20.00	25.00	19.00	24.00	
	Percentiles	25		6.00	9.25	6.00	6.00	6.50	9.25	16.25	19.00	16.25	6.00	14.25	6.00	6.00
		75		14.75	14.00	11.00	12.75	11.50	17.50	23.00	23.00	22.00	16.00	21.00	9.00	6.00

Figure Legends

Figure 1. Recent BJC carbapenem-resistant *Acinetobacter* (CRAb) cases are principally non-hospital acquired (nHA) and associated with isolates displaying a unique antibiotype (ast). (a) Annual CRAb cases that were hospital-acquired (HA) and nHA (gray and black bars, respectively) and annual percentage of cases that were nHA (“nHA ratio”, dots). **(b)** Annual CRAb cases associated with index isolates exhibiting each antibiotype (colored bars) and annual percentage of cases associated with ast-5 isolates (“ast-5 ratio”, dots). Y-axes values in all panels represent rolling two-year average for respective ratios. nt, non-typeable due to missing AST data (see **Figure S1B**). Raw values are listed in **Data S1**.

Figure 2. Unique ast-5 antibiotype is linked to prevalent CRAb lineage BJC ST499^{Pas}. (a) Maximum likelihood phylogenetic tree of BJC *A. baumannii* index isolates according to core genome alignment. ST^{Pas} containing CRAb isolates are highlighted and labeled. Inner rings represent isolate metadata according to the corresponding keys surrounding the tree. Outer rings show AST results grouped by class and flanked by boxes denoting the presence (filled box) or absence of listed genes putatively conferring class resistance. For clarity, only genes exclusive to resistant isolates are included. Isolate metadata are listed in **Data S2**, and all identified resistance genes are listed in **Data S4**. **(b-d)** Antibiotic susceptibility according to zone of clearance, of genotyped *Ab* index isolates (red dots) and non-genotyped *Acbc* index cultures (black dots) identified between January 2017 and December 2019. Non-genotyped CRAb were grouped with ST499^{Pas}, ST406^{Pas} or “other” isolates according to antibiotype. Backgrounds highlight ranges for “resistant” (dark) and “intermediate” (light) susceptibility, per CLSI guideline interpretation. Box-plot center lines denote medians, while box limits denote upper and lower quartile values (listed in **Table S5**). Whiskers denote 1.5x interquartile range. Medians

compared according to Mann-Whitney test with Bonferroni adjustment for multiple comparisons.

*, $p < 0.05$; **, $p < 0.005$; ***, $p < 0.0005$; ****, $p < 0.00005$.

Figure 3. Clonal clusters were identified exclusively among ST499^{Pas} and ST406^{Pas}

isolates. (a,b) Network analyses demonstrating relatedness of isolates according to core genome SNP distance (panel A) and whole genome ANI (panel B). Each node represents an isolate, with nodes color-coded according to isolation hospital (border) and calendar quarter (fill), per key in panel B. Edges represent interactions that meet cutoffs, with degree of relatedness represented by edge width and color; edge distances were manually adjusted for clarity. Insets demonstrate histograms of values from pairwise comparisons between isolates obtained from different patients (light gray) or isolates obtained from the same patient (dark gray). Only extreme values are displayed, for clarity. Dotted lines denote cutoff values for edges in respective networks. **(c)** Maximum likelihood tree derived using 1881 SNPs identified from alignment of 2.63 Mbp in 2702 core genes of ST499^{Pas} isolates. **(d)** Maximum likelihood trees derived using 16644 SNPs identified from alignment of 2.09 Mbp in 2110 core genes of ST406^{Pas} isolates. For clarity in panels C and D, only bootstrap values <90% are included. Each leaf is color-coded according to isolation hospital (square) and calendar quarter (circle), per key in panel D. Isolates obtained from the same patient share label color, with index isolates in bold. Isolates belonging to clonal clusters highlighted in panels A and B, are denoted by branch color and vertical labels in panel C and D.

Figure 4. Epidemiologic links within ST499^{Pas} clonal clusters. (a,b) Unrooted version of ST499_p phylogenetic tree from **Figure 3C**. Panel B is ~10x enlargement of region highlighted by gray rectangle in panel A. Clonal clusters are denoted by colored branches. Tree leaf symbols

denote hospital of isolation (see panel B inset key). BJC isolates obtained from the same patient share label color. **(c-f)** Clinical timelines of patients (labeled A-H on Y-axis) in 499-1, 499-2, 499-5 and 499-6, respectively. As presented in the key adjacent to panel C, colored symbols on each patient timeline denote dates of hospitalizations (wide rectangles), long term care facilities admissions (LTF, narrow rectangles), outpatient clinic visits (CLIN, circles), and pertinent clinical cultures (triangles with labels colored according to culture specimen). Full color-coded key is in **Figure 5**. Shaded areas between timelines highlight shared exposures suspected of facilitating clonal propagation (see text). 28-month span represented on X-axis of panel F, is conserved in all panels. WGS, whole genome sequencing; EMR, electronic health record; *Ab*, *A. baumannii*.

Figure 5. Patient timelines of clonal clusters lacking obvious epidemiologic links. Clinical timelines of patients (labeled A-E on Y-axis) in clonal clusters 449-3, cluster 499-4 and 406 (from top to bottom). Colored objects on each patient timeline (see key at bottom) denote dates of hospitalizations (wide rectangles), long-term care facilities admissions (LTF, narrow rectangles), outpatient clinic visits (CLIN, circles), and pertinent clinical cultures (triangles, labels colored according to culture specimen). 28-month span is conserved in all panels. Colored key also corresponds to patient timelines in **Figure 4**. WGS, whole genome sequencing; EMR, electronic medical record; *Ab*, *A. baumannii*.

Figure 6. The spectrum of CRAb propagation habits ranging from stable intrahospital pools (left) to centering around outpatient environments (right). LTF, long-term care facilities; trx, patient transfers.

Supplementary Figure Legends

Figure S1. Analysis workflows. (a) Overview of banking and processing of *Acinetobacter* clinical isolates collected between July 2017 and May 2019. All isolates were reported as *Acinetobacter calcoaceticus-baumannii* complex (Acbc) or *Acinetobacter* species (Aspp) according to MALDI-TOF performed in the BJC clinical microbiology laboratory. **(b)** Algorithm for assigning antibiotype according to antimicrobial susceptibility testing (AST). All BJC CRAb index cultures isolates (n=928) were typed ast-1 through ast-5 according to whether they were reported as resistant (R), intermediate (i), or susceptible (s) to listed antibiotics. If an isolate's AST result was not available (n/a) for any antibiotic in the algorithm, it was classified as non-typeable (nt). The number of index cultures in each category is noted in parentheses. GM, gentamicin; MEM/IPM, meropenem and/or imipenem; SXT, trimethoprim/sulfamethaxazole; TET/DOX, tetracycline and/or doxycycline.

Figure S2. BJC CRAb isolate beta-lactamase gene content and beta-lactam AST. (a) ST^{Pas} containing CRAb isolates are highlighted and labeled. First colored row denotes antibiotype, and subsequent rows denote AST results to beta-lactam antibiotics routinely tested with all *Acinetobacter* isolates in the BJC CML. Bottom boxes denote presence/absence of beta-lactamase genes, listed on right and grouped according to homologous lactamase types (bold). For clarity, only genes identified in CRAb isolates are included. Isolate metadata are listed in **Data S2**, and all identified resistance genes are listed in **Data S4. (b)** AST results according to zone of clearance, of genotyped *Ab* index isolates (red dots) and non-genotyped Acbc index cultures (black dots) identified in BJC hospitals between January 2017 and December 2019. Isolates are grouped according to antibiotype. Backgrounds highlight ranges for “resistant” (dark) and “intermediate” (light) susceptibility, per CLSI guidelines. Box-plot center lines denote medians, while box limits denote upper and lower quartile values (listed in **Table S5**). Whiskers

denote 1.5x interquartile range. Medians compared according to Mann-Whitney test with Bonferroni adjustment for multiple comparisons. *, $p < 0.05$; **, $p < 0.005$; ***, $p < 0.0005$; ****, $p < 0.00005$.

Figure S3. Global core genome phylogeny of *A. baumannii* isolates. Maximum likelihood phylogenetic tree comparing 1647 core genes shared by select *A. baumannii* genomes available on NCBI and BJC isolates. The outer ring depicts the medical center in which the isolate was identified. Clades corresponding to the predominant ST^{Pas} are color coded and labeled. ST406^{Pas} and ST1088^{Pas} are single locus variants. Black dots denote separate phylogenetic groups of BJC ST2^{Pas} and ST406^{Pas} isolates. For clarity, only bootstrap values $\leq 90\%$ are included on corresponding branches.

Figure S4. Sensitivity analyses of criteria for assigning presumptive clonal cluster. (a,b) Networks demonstrating relatedness of isolates according to different cutoffs (listed above networks) for core genome SNP distance (cgSNP, panel a) and whole genome ANI (wgANI, panel b). Each node represents an isolate, with nodes color-coded according to isolation hospital (border) and clonal cluster according to **Figure 3** (fill), per key in panel B. Edges represent interactions that meet cutoffs, with degree of relatedness represented by edge width and color. Node positions and edge distances were manually adjusted for better comparison with **Figure 3** and clarity. **(c)** Table listing network changes as result from adjusting the cutoff values. “Additional isolates*” column lists the additional isolates (and corresponding sequence type/clonal cluster in parentheses) that are eligible for inclusion compared to one step stricter cutoffs.

Figure S5. Confirmation of ST499^{Pas} and ST406^{Pas} phylogeny by alternative methodology.

(a,b) Maximum likelihood phylogenetic trees according to the presence-absence of accessory genes in ST499^{Pas} (panel a) and ST406^{Pas} (panel b) isolates. For clarity, only bootstrap values $\leq 90\%$ are included on corresponding branches. Isolates obtained from the same patient share label color, with index isolates in bold. Tree scale in key applies to both trees. **(c,d)** Maximum likelihood phylogenetic trees according to the core genome alignment of ST499^{Pas} (panel c) and ST406^{Pas} (panel d) isolates, corrected for computationally predicted recombination events using ClonalFrameML software. Isolates obtained from the same patient share label color, with index isolates in bold. Isolates belonging to clonal clusters as identified in **Figure 3**, are highlighted by color or denoted by branch color and vertical labels. Isolate WU_MDCI_Ab065 is assigned to cluster 499-4.

Supplementary Data

Data S1 (DataS1_BJCAcbcEpi.xls)

Three tables containing raw data of epidemiological analysis of *Acbc* cases, BJC 2007-2019.

Data S2 (DataS2_BJC_IsolateList.xls)



Table listing name, sequence information and clinical metadata of BJC isolates included in genomic analysis.

Data S3 (DataS3_NCBIisolates.xls)


Table containing list of NCBI genomes and corresponding isolates, included in this study.

Data S4 (DataS4_BJC_IsolateARGanalysis.xls)


Results of genomic analysis for antimicrobial resistance genes and other genomic element, BJC isolates.

a**b**


a




b




c




d







a



b




c




d





e




f









Hospital care






Non-hospital care






a**b**

a**b**





C

	Distance cutoff	Edges (n)	Median Distance	Mean Distance	Nodes	Additional isolates*
<i>Core genome SNP (n)</i>						
	5	370	4	3.3	58	
	10	729	5	5.3	58	
	15	768	6	5.6	60	235 (499), 245 (499-6)
	20	821	6	5.5	62	36 (406), 165 (406)
	30	889	6	7.9	64	81 (406), 202 (499)
	None	5965	26521	21620.3	110	NA
<i>Whole genome ANI (%)</i>						
	99.997	211	99.998	99.998	54	
	99.995	396	99.997	99.997	58	86, 91 (406), 94 (499-1), 98 (499-3)
	99.993	510	99.996	99.996	61	269/270 (78), 133 (406)
	99.99	557	99.996	99.996	63	136 (406), 249 (406)
	None	5965	97.996	96.37	110	N/A

